Raymond James Financial Inc. Acquires New Position in REGENXBIO Inc. (NASDAQ:RGNX)

Raymond James Financial Inc. bought a new stake in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 73,510 shares of the biotechnology company's stock, valued at approximately $568,000. Raymond James Financial Inc. owned 0.15% of REGENXBIO as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. GAMMA Investing LLC lifted its holdings in REGENXBIO by 273.1% in the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company's stock valued at $27,000 after acquiring an additional 2,510 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in REGENXBIO during the 4th quarter worth approximately $54,000. Dynamic Technology Lab Private Ltd purchased a new position in REGENXBIO in the fourth quarter worth $79,000. EntryPoint Capital LLC purchased a new position in REGENXBIO in the 4th quarter valued at approximately $97,000. Finally, Teacher Retirement System of Texas raised its holdings in shares of REGENXBIO by 19.9% in the fourth quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company's stock worth $97,000 after acquiring an additional 2,088 shares during the last quarter. 88.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. HC Wainwright reduced their price target on shares of REGENXBIO from $36.00 to $34.00 and set a "buy" rating on the stock in a research report on Monday, March 17th. The Goldman Sachs Group lowered their price target on REGENXBIO from $14.00 to $12.00 and set a "neutral" rating on the stock in a report on Thursday, April 17th. Raymond James initiated coverage on REGENXBIO in a research note on Friday, February 7th. They set an "outperform" rating and a $27.00 price objective for the company. Chardan Capital reiterated a "buy" rating and set a $52.00 price target on shares of REGENXBIO in a report on Thursday, March 20th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $30.00 target price on shares of REGENXBIO in a research report on Tuesday, January 21st. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $31.63.

REGENXBIO Stock Up 5.2 %

Shares of REGENXBIO stock traded up $0.37 during trading on Friday, reaching $7.52. The company's stock had a trading volume of 872,904 shares, compared to its average volume of 849,180. The company has a market cap of $376.88 million, a price-to-earnings ratio of -1.50 and a beta of 1.11. REGENXBIO Inc. has a 52-week low of $5.04 and a 52-week high of $16.85. The firm's 50-day moving average is $7.32 and its two-hundred day moving average is $8.00.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last announced its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, topping analysts' consensus estimates of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The business had revenue of $21.21 million for the quarter, compared to analysts' expectations of $23.70 million. On average, equities research analysts anticipate that REGENXBIO Inc. will post -4.84 EPS for the current year.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.